ArticleFrontiers in microbiology2026
Evaluation of a COX-2 fluorescent probe for adjunctive quantitative assessment of BV-associated inflammatory severity.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Bacterial vaginosis (BV) is a prevalent lower genital tract infection linked to significant reproductive health complications. Current diagnostics are subjective or non-quantitative for clinical use. This study aims to evaluate a novel cyclooxygenase-2 (COX-2)-targeting fluorescent probe as an adjunctive quantitative tool for assessing BV-associated inflammatory severity within a standard BV diagnostic workflow. Methods: A murine BV model was established using estrogen-pretreated C57BL/6J mice infected vaginally with pathogens. Vaginal lavage samples from both BV and sham control mice were analyzed with the COX-2 probe. Clinically, vaginal secretions from 45 outpatients were grouped into Normal and BV categories based on microecological criteria. COX-2 fluorescence was measured in all samples and correlated with microbiological parameters. Results: The BV model showed elevated IL-1β and reduced IL-10 ( Conclusions: The COX-2-targeting nano-probe demonstrates strong correlation with key BV indicators and enables quantitative severity assessment. It represents a promising adjunctive quantitative tool for objective and stratified assessment of BV-associated inflammatory severity, with potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.